Introduction
The aim of this study is to investigate the dependency of patient risk stratification on TVD, defined by different PET-AS, when prognostic models are developed with radiomic features.
Aims & Objectives
Consecutive patients (n=427) with biopsy-proven Oesophageal cancer staged with PET/CT were included. Patients received 4MBq/kg of 18 F-FDG before image acquisition at 90 minutes. In each case, the Metabolic Tumour Volume (MTV) was defined using Clustering Means (KM2), General Clustering Means (GCM3), Adaptive Thresholding (AT) and Watershed Thresholding (WT) PET-AS. Table 1 , describes PET-AS implementations. All tumour segmentations were reviewed by a radiologist to ensure accuracy. Prognostic models using identical clinical data but different radiomic features defined by each segmentation method were developed. Changes in patient classification between risk groups were analysed. A p-value of <0.05 was considered statistically significant. Primary outcome was overall survival (OS).
Materials & Methods

Results
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The equations for each model from different segmentation methods are listed in Table 2 . Age, treatment and radiological stage were significant variables in all prognostic models. Skewness was a significant variable in GCM3 and WT based models. Table 3 shows the number (percentage) of patients that changed risk stratification between developed prognostic models. Figure 1 shows the overall survival for the KM2, GCM3, AT and WT developed models. There was no significant difference in median OS between KM2, GCM3, AT and WT low-risk groups (P > 0.5), intermediaterisk (P > 0.5) and high-risk groups OS (P > 0.5).
Radiomic features are dependent on the PET-AS used and consequently influence patient risk stratification when incorporated into prognostic models. Methods used to define the metabolic tumour volume in PET radiomic studies should be standardised. 
